1月20日 - ** 药物开发商Rein Therapeutics RNTX.O股价盘前上涨2.5%至1.24美元
** 该公司称 (link)，欧洲监管机构授予其用于治疗特发性肺纤维化（IPF）的实验性疗法LTI-03孤儿药地位，IPF是一种致命的肺部疤痕疾病。
** IPF 会造成不可逆转的肺损伤，导致呼吸困难
** 公司称，临床前试验的早期数据显示，患者的存活率和肺功能都有所改善
** RNTX公司的LTI-03是一种合成肽，旨在保护肺细胞和阻断导致瘢痕形成的信号；该公司表示，该药物还拥有美国孤儿药地位。
** 公司计划在美国、英国、德国、波兰和澳大利亚开展进一步试验
** 截至上次收盘，该公司股价在过去一年中下跌了约 50%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.